Kornimate/medical-research-clean huggingface dataset:
eating, sleeping, consoling for neonatal withdrawal (esc-now): a function-based assessment and management approach

Conditions: Neonatal Opiate Withdrawal Syndrome

Summary: the overall objective is to determine if the esc care approach will reduce the time until infants being managed for nows are medically ready for discharge.

this study will randomize institutions in blocks to transition from usual institutional care for infants with nows to the esc care approach at a randomly allocated transition period (from usual care to the esc care approach). during the initial birth hospitalization, the clinical site research team will collect data under waiver of consent for infants who meet eligibility criteria. the site research team will obtain informed consent from the legal guardian(s) to obtain long-term outcomes for eligible infants and caregivers. clinical site research team members may obtain this consent at any point during the hospital stay for infants who meet the trial's inclusion criteria. this data will allow the protocol study team to short- and long-term outcomes for infants managed with the esc care approach compared to usual institutional care.

Eligibility criteria:
inclusion criteria: * 1. the infant is being managed for nows at an eligible site (i.e., receiving non-pharmacologic care, assessments for withdrawal severity, +/- pharmacologic care) 2. the infant is ≥ 36 weeks gestation 3. the infant satisfies at least 1 of the following criteria: 1. maternal history of prenatal opioid use 2. maternal toxicology screen positive for opioids during the second and/or third trimester of pregnancy 3. infant toxicology screen positive for opioids during the initial hospital stay exclusion criteria: * 1. infant has major birth defect(s) 2. infant has neonatal encephalopathy (inclusive of hypoxic ischemic encephalopathy), a metabolic disorder, stroke, intracranial hemorrhage, or meningitis diagnosed by 60 hours of life 3. infant was receiving respiratory support (any positive pressure or oxygen therapy) unrelated to pharmacologic treatment for nows at 60 hours of life 4. infant was receiving antimicrobial(s) at 60 hours of life 5. infant has received any major surgical intervention in the first 60 hours of life 6. postnatal opioid exposure other than for treatment of nows in the first 60 hours of life 7. outborn infants transferred at \>60 hours of life or treated with opioids for nows at the transferring hospital

Keywords: nows
the genpet study - an imaging study of fch-pet-ct in men with prostate cancer and a dna repair gene mutation.

Conditions: Prostate Cancer; BRCA Mutation; Mismatch Repair Gene Mutation; ATM Gene Mutation; HOXB13 Germline Mutation; CHEK2 Gene Mutation; PALB2 Gene Mutation

Summary: the aim of the study is to determine if pet-ct imaging (using contrast recommended in clinical guidelines) is superior to combined bone scan and mri/ct of the abdomen \& pelvis in detecting the increased incidence of metastasis (nodal/distant outside the pelvis) in men with prostatic carcinoma with mutations in any of the following germline dna repair genes brca1, brca2, msh2, msh6, mlh1, pms2, chek2, palb2, atm.


Eligibility criteria:
inclusion criteria: * confirmed pathogenic germline mutation in any of the following genes brca1, brca2, msh2, msh6, mlh1, pms2, chek2, palb2 or atm. * over the age of 18 * diagnosed with prostate cancer and at a time when staging imaging is clinically indicated; either: * at a new diagnosis * biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy * patients on active surveillance with a psa doubling time of 6 months or less exclusion criteria: * diagnosis of other malignancy (excluding basal cell cancer/squamous cell cancer of the skin) within five years of diagnosis * known metastatic prostate cancer, both local and distant * patients who have received any oncological treatment within the last six months * patients on any investigational drug treatment * patients on steroids * known history of inflammatory/infective diseases (e.g. sarcoidosis, tuberculosis, inflammatory bowel disease) * contraindications to having an mri using the standard mri checklist (e.g. pacemakers, aneurysm clips, claustrophobia)

Keywords: fch-pet-ct psma-pet-ct
support of the sexual health in oncology

Conditions: Oncology; Sexual Health

Summary: implementation of sexual health support program in oncology department. this program is organized in 3 axes. one is to inform the side effects of treatment on sexual health. there is a counselling team (nurse, esthetician,sexologue..etc) to raise the subject with patient and partner . finally, the oncologist continue during the treatment to evaluate the benefit of this program and adapt their counselling according to the needs


Eligibility criteria:
inclusion criteria: * all patient consulting in oncology service * age \> 18 years * accepting to participate exclusion criteria: * age\< 18 years * refusing to participate
age and refraction in predicting myopia progression in covid-19

Conditions: Refraction Error; Myopia

Summary: to determine the longitudinal changes of age and refraction in predicting myopia progression with risk under the coronavirus disease 2019 (covid-19) pandemic in a 3-year follow-up of a chinese cohort.

this was part of the large-scale tianjin eye study, a population-based cohort study that longitudinally investigates the relationship between the age, refraction, and development of childhood re in tianjin, china.

Eligibility criteria:
inclusion criteria: * no concurrent eye disease; * age 6-15 years. exclusion criteria: * significant systemic illnesses * ocular conditions that could affect the corneal curvature, including congenital corneal diseases, * pterygium, keratoconus, other corneal degeneration or dystrophy conditions, * media opacity, uveitis, glaucoma * a history of intraocular surgery, refractive surgery, * neurologic or retinal diseases, current corneal refractive therapy (ortho-k), * low-dose atropine therapy for myopia control
direct repair surgery for spondylolysis of lumbar in young population

Conditions: Spondylolysis

Summary: lumbar spondylolysis is a relatively common condition that causes severe and perennial back pain in young populations. conservative treatment of this condition may be futile, and may eventually require surgical treatment such as direct repair of pars defect and a segmental lumbar fusion with an anterior or posterior approach. recently, of surgical treatment methods for spondylolysis, direct repair surgery of pars defect has been focused due to its inherited strengths. most importantly, fusion surgery caused the affected segment to lose the nature range of motion and furthermore adjacent segment to be adversely affecting such as adjacent disc disease or degeneration, while direct repair theoretically could preserve the motion of the affected segment, which do not cause the adjacent segment problems as being the fusion surgery, as well as could produce better surgical outcomes with relatively less invasive technique as compared to fusion surgery. moreover, previous articles have demonstrated that the direct repair surgery for spondylolysis of lumbar spine could achieve great functional and radiological outcomes. however, most of the previous studies was conducted using lower level designed study such as retrospective and small sample size, thereby prior literature does not provide clear information on the therapeutic outcome of direct repair for lumbar spondylolysis, especially for managing spondylolysis of young population. therefore, the investigators aimed to evaluate and determine the outcomes of direct repair surgery for lumbar spondylolysis in young population. to our knowledge, this is the first report that describes the functional and radiological outcomes of direct repair for spondylolysis in young populations with prospective cohort study design and relatively large sample size.


Eligibility criteria:
inclusion criteria: * patients for whom conservative treatment for six months and three-times injection treatments had failed * a follow-up period of one year or more after surgery exclusion criteria: * patients with abnormal muscle activity or ambulation such as parkinsonism and neuromuscular disease. * patient inability to accurately record results of preoperative and postoperative questionnaires due to problems such as a history of stroke, dementia, or major medical illness that required intensive treatment * patient follow-up was limited to one year or less

Keywords: spondylolysis lumbar spine young population direct repair union rate functional outcome
rescue intracranial stenting in acute ischemic stroke

Conditions: Acute Stroke; Ischemic Stroke; Intracranial Atherosclerosis; Stent Stenosis; Cerebral Ischemia; Stent Occlusion; Stroke, Ischemic; Intracranial Hemorrhages; Thrombotic Stroke, Acute

Summary: in acute ischemic stroke caused by intracranial large vessel occlusion, rescue intracranial stenting has been recently a treatment option to achieve recanalization in patients with the failure of mechanical thrombectomy. nevertheless, there are few studies supporting this beneficial treatment in two cerebral circulations. we aimed to analyse whether the use of rescue intracranial stenting would improve prognosis of patients at 3 months.

in asia population, large intracranial arterial stenosis lesion accounts for more than 30% in common causes of ischemic stroke, compares with about 10% in caucasian population every year. normally, in human brain, there are about 130 billion neurons but they are lost equivalent to their losses in approximately 3.6 years of normal aging in case of a large vessel ischemic stroke untreated each hour. consequently, after the success of 5 randomized controlled trials about the mechanical thrombectomy, which have been done from december 2010 to december 2014, all of guidelines recommended this technique as the first-line treatment in acute ischemic stroke. however, the hermes meta-analysis showed that revascularisation failure ratio 28.9% in patients older than 80 years. recently, in case of mechanical thrombectomy failure, many studies suggested the rescue intracranial stenting could be alternative urgently needed treatment to achieve permanent recanalization which is one of the most important factors impacting on clinical outcomes after acute ischemic stroke. hence, the aims of our study were to assess both the "non-poor" outcome at 3 months and the symptomatic intracerebral hemorrhage relating to procedure in patients receiving rescue intracranial stenting.

Eligibility criteria:
inclusion criteria: * evidence of intracranial large vessel occlusion. * absence of intracranial hemorrhage. * severe stenosis or reocclusion after mechanical thrombectomy. exclusion criteria: * tandem lesion. * loss to follow-up after discharge. * a severe or fatal combined illness before acute ischemic stroke.

Keywords: acute ischemic stroke rescue intracranial stenting symptomatic intracerebral hemorrhage mri 3 tesla rehabilitation
surgical margin assessment by 3d ultrasound

Conditions: Tongue Cancer; Squamous Cell Carcinoma; Head and Neck Cancer

Summary: complete removal of cancer encircled by a secure margin of healthy tissue is the aim of surgical oncology. a close or positive surgical margin reported by pathologist typically ends in adjuvant therapies (re-surgery and/or radiotherapy), which come with prognostic risks and financial cost. therefore, ex-vivo imaging of removed cancer tissue may assist in margin evaluation. in this study, investigators aimed to investigate the correlation of 3d ultrasound to histopathology to assess tongue tumor margin status.


Eligibility criteria:
inclusion criteria: * patients with biopsy-proven oral tongue squamous cell carcinoma scheduled for surgical treatment * t1-t2 staging on cross-sectional imaging exclusion criteria: * age \< 18 yrs * t3-t4 staging * unable to understand the verbal or written information * prior radiotherapy treatment of oral cavity cancer

Keywords: 3d ultrasound histopathology ultrasonography three dimensional imaging cancer diagnosis tongue tumor
a 12-month study of lasmiditan (ly573144) treatment in children aged 6 to 17 with migraine

Conditions: Migraine

Summary: the reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. the study will last about 12 months and may include up to 7 visits.


Eligibility criteria:
inclusion criteria: * participants must have completed study h8h-mc-lahx (nct03988088) or study h8h-mc-lahv (nct number to be determined) * participants must weigh at least 15 kilograms (kg) exclusion criteria: * participants must not be pregnant or nursing * participants must not have any acute, serious, or unstable medical condition * participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator

Keywords: acute long-term open label safety
the effects of hesperidin on metabolic syndrome

Conditions: Metabolic Syndrome

Summary: to study the effects of hesperidin supplement in patients with metabolic syndrome, 50 patients will be randomly allocated to control group or 2 capsules hesperidin for 12 weeks; both groups will be advised to adherence the investigators' diet and exercise program too. at the first and the end of the intervention, metabolic factors will be assessed and compared between groups.


Eligibility criteria:
inclusion criteria: * age of 18 to 70 years * having 3 of 5 of high blood sugar, hypertension, high tg, high waist circumference, low hdl exclusion criteria: * pregnancy or lactation * a history of cardiovascular disease, pulmonary disease, renal disease \& celiac disease; cirrhosis * following program to lose weight in recent 3 mo
determination of nerve growth factor (ngf) expression in pediatric patients with severe burns: a pilot study

Conditions: Burns

Summary: the goal of this observational study is to determine the blood values of ngf in severely burned patients, to describe any changes over time and finally to correlate the expression of ngf to the severity of the burn. the main question it aims to answer is: - describe ngf values in severely burned pediatric patients and to evaluate their correlation with the severity of the burn and the extent of the burned skin surface by measuring the circulating levels of ngf in pediatric patients. participants will undergo blood sampling on days 2,7,14 and 30 after the traumatic event for the clinical follow-up envisaged by the internal protocol.

severe pediatric burns, characterized by an extension greater than 10% of the total body surface or by the involvement of particular districts such as the hands, face, airways or genitals, are characterized by multisystem involvement, which often requires intensive care support. the epidermis begins to develop from the superficial ectoderm at the end of the fourth week of gestation when the neural tube separates from the overlying ectoderm. consequently, the ectoderm gives rise to both the nervous system and the epithelium. in particular, the nerve growth factor (ngf) is a neurotrophic factor that plays a fundamental protective role in the development and survival of neurons. in fetal skin, ngf is synthesized in both the epithelium and mesenchyme, but the highest amounts of ngf messenger ribonucleic acid are found in the epithelium. there are currently no studies investigating the expression of ngf in severe burns. the common embryonic origin of the skin and the neurological system may hold the key to new research opportunities to understand the regenerative response and in particular the role of growth factors such as ngf in the skin repair mechanism in severe burns . the hypothesis of the study is based on the possibility that skin burns may be related to an increased expression of circulating ngf in the blood. however, there are no data in literature on this issue and the behavior of ngf in patients affected by burns is not known, either in adult or pediatric patients. aim to describe ngf values in severely burned pediatric patients and to evaluate their correlation with the severity of the burn and the extent of the burned skin surface by measuring the circulating levels of ngf.

Eligibility criteria:
inclusion criteria: * patients suffering from severe burns exclusion criteria: * major congenital malformations * antibiotic treatment 48 hours prior to admission * norepinephrine infusion \> 0.5 mcg/k/min * lack of informed consent from parents or legal guardians

Keywords: nerve growth factor pediatric patient
covid-19 vaccination take-up

Conditions: Covid19; Vaccination

Summary: in this work, the investigators are partnering with contra costa health services (cchs), the department of health in contra costa county, ca, to measure covid-19 vaccinations and other covid-19 related preventive health behaviors in the county's medicaid managed care population. this work will test ways to increase covid-19 vaccine uptake. the investigators hypothesize that small financial incentives and other low-cost behavioral nudges can be used to increase vaccine uptake and reduce disparities in uptake among diverse racial/ethnic minority populations.


Eligibility criteria:
inclusion criteria: * age 18 and over * member of contra costa health plan (cchp) exclusion criteria: * contraindications to vaccination, as determined by county health plan or other medical staff.

Keywords: covid19 vaccination
intravenous lidocaine randomized comparative effectiveness trial

Conditions: Abdominal Pain

Summary: this is a randomized, double-blind, emergency department based, comparative effectiveness study of two medication for acute abdominal pain: intravenous lidocaine and intravenous hydromorphone. patients will be enrolled during an emergency department visit and followed throughout their emergency department course and then by telephone 7 days later.


Eligibility criteria:
inclusion criteria:eligible patients are those who present to an ed for treatment of acute abdominal pain. acute will be defined as pain for no more than seven days. at the time of enrollment, the ed treatment plan must include use of an intravenous opioid. exclusion criteria: patients will be excluded from participation if they have cardiac conduction system impairment (qtc duration \> 0.5s, qrs duration \> 0.12s, or pr interval duration \> 0.2s), known renal (ckd \>2) or liver disease (childs-pugh b or greater), are hemodynamically unstable, as determined by the attending physician, are pregnant or breastfeeding, or have a known allergy to either medication. patients will also be excluded if they have used prescription or illicit opioids within the previous week, or if they have a chronic pain disorder, defined as use of any analgesic medication on more days than not during the month preceding the acute episode of pain. patients weighing \ 120kg will be excluded. -
comparison of sequencing and pna clamping of egfr gene in patients with non-small cell type lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: using dna acquired from tumor tissue, sequencing and pna-clamping for egfr gene will be performed. the detection rates of egfr mutation will be compared using paired samples.

single arm, open label, prospective, observational study of gefitinib treatment for locally advanced (stage iiib) or iv (metastatic) or relapsed nsclc patients. using dna acquired from tumor tissue, sequencing and pna-clamping for egfr gene will be performed. the detection rates of egfr mutation will be compared using paired samples.

Eligibility criteria:
inclusion criteria: * locally advanced stage iiib not suitable for curative therapy or stage iv (metastatic) disease or relapsed nsclc * ecog performance status 0\~2. * written informed consent * female or male patients aged 18 years or over, eligible for treatment for nsclc exclusion criteria: * previous exposure to egfr-tki * concomitant use of other anti-cancer drugs with egfr-tki * patients without available tumor dna * as judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) * evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study * pregnancy or breast-feeding women (women of child¬bearing potential). women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy.

Keywords: non-small cell lung cancer
tear cytokine analysis as a prediction or diagnostic marker in ocular gvhd

Conditions: Chronic Graft-versus-host Disease

Summary: investigate the profiles of tear cytokines in patients who underwent stem cell transplantation (sct) and attempted to determine the applicability of tear cytokines in the diagnosis of chronic graft-versus-host disease (gvhd). evaluate tear cytokines as biomarkers of chronic ocular gvhd severity.


Eligibility criteria:
inclusion criteria: * the patients patients aged 20-60 years who visited the clinic 3-12 months after sct were included in the study. exclusion criteria: * the patients with histories of ocular surgery; ocular injury; and ocular diseases such as ocular infection, allergy, and autoimmune disease, as well as patients with long-term use of topical ocular medications except artificial tears.

Keywords: stem cell transplantation (sct)